• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Slides for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
FDA Core Presentations, Vivitrol (Naltrexone for Extended-Release Injectable Suspension), for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDF - 586KB)
 Rachel Skeete, M.D., DAAP, ODE II, OND, CDER, FDA
Srikanth C. Nallani, Ph.D., Office of Clinical Pharmacology, OTS, CDER, FDA
Feng Li, Ph.D., Division of Biometrics II, Office of Biostatistics, OTS, CDER, FDA 
 
Tejashri Purohit-Sheth, M.D., Branch Chief, Good Clinical Practice II, Division of Scientific Investigations, Office of Compliance, CDER, FDA (PDF – 186KB)
 
Robert O’Neill, Ph.D., Director, OB, OTS, CDER, FDA (PDF – 1.56MB)
 
 
Sponsor
Alkermes, Inc. Core Presentations, Vivitrol (Naltrexone for Extended-Release Injectable Suspension), for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDF – 4.96MB)